美沙拉嗪及SASP治疗溃疡性结肠炎的临床疗效比较

The clinical effecacy comparison of mesalazine and SASP in the treatment of ulcerative colitis

目的探讨并比较美沙拉嗪与柳氮磺吡啶两组药物在治疗活动期轻度与中度溃疡性结肠炎的临床疗效与副作用。方法将我院自2009年12月至2011年6月期间收治活动性轻度或中度溃疡性结肠炎患者72例随机分成美沙拉嗪治疗组(观察组)38例和柳氮磺吡啶治疗组(对照组)34例,两组均连续治疗56d,观察两组患者的临床症状、各生化指标、结肠镜下黏膜状况以及副作用情况。结果通过56d的治疗,观察组患者的病情出现明显改善,观察组的总有效率明显高于对照组,两组比较差异显著(P<0.05),具有统计学意义。观察组与对照组患者在治疗后第56天时其腹痛、腹泻、脓血便、黏膜充血水肿、糜烂出血、溃疡以及血管模糊等情况均出现改善,两组患者均表现出腹痛减轻以及大便次数与脓血减少,内镜下黏膜的外观良好。两组患者在第56天时结肠黏膜组织学分值均较治疗前显著下降(P<0.05),具有统计学意义。两组患者的副作用发生率之间比较差异显著(P<0.01),具有统计学意义。上述副作用均在治疗过程中给予及时对症处理,均未对治疗过程产生影响。结论采用美沙拉嗪对于活动期轻度与中度溃疡性结肠炎疾病的治疗方面具有令人满意的临床疗效,其临床疗效明显优于柳氮磺吡啶治疗组,而且应用美沙拉嗪治疗的副作用明显减少,值得临床上广泛推广并应用。

Objective To investigate and compare the mesalasine and sulfasalasine in two groups of drugs in the treatment of mild and moderate active ulcerative colitis clinical efficacy and side effects. Methods In our hospital from 2009 December to 2011 June were mild or moderate activity of ulcerative colitis patients were randomly divided into 72 cases of mesalazine in the treatment group （observation group） and 38 cases of suffasalazine treatment group （control group） in 34 cases, two groups were treated with continuous 56 d, ob- serve two groups of patients clinical symptoms ~ various biochemical indexes, colonoscopic mucosal condition as well as the side effects. Results After 56 d treatment, the observation group the patient＇ s condition improves significantly, the observation group in the total efficiency was significantly higher than that of the control group, the difference between the two groups is significant （ P 〈 0. 05 ）, with statistical significance. The observation group and the control group patients in the treatment of 56 d after the abdominal pain, diarrhea, stool with pus and blood, mucosal hyperemia edema, erosion, ulcer hemorrhage and vascular fuzzy situation are improved, two groups of patients showed abdominal pain and diarrhea stool frequency and reduced, endoscopic mucosal look good. Two groups of patients in the 56d credit value of colonic mucosa were significantly decreased （P 〈 0.- 05 ）, with statistical significance. Two groups of patients, the incidence of side effects between marked differ- ence （P 〈 0. 01 ）, with statistical significance. The side effects during treatment to give timely symptomatic treatment, not to influence the treatment process. Conclusion Using mesalamine for mild and moderate active ulcerative colitis disease treated with satisfactory clinical curative effect, the clinical curative effect of sul- fasalazine treatment group, and the application of mesalazine in the treatment of side effects were significantly reduced, is worth the clinical widely popularization and application.